Stay in Front with Gadovist®

Behind Every Dose of Gadovist
®
is Bayer

At Bayer, we believe that there is only one way to go: Forward. We share a joint vision with you to improve patient’s lives from diagnosis to care, because everyone deserves clear answers about their health.

Innovation
Striving to Propel the Industry Forward

Bayer is committed to bringing you the latest advancements in the field of diagnostic imaging, through cutting-edge technology and/or artificial intelligence. We invested €5.4 billion into crucial research and development in 2021 alone.

Advancing Knowledge
Backed by an Extensive Publication Record

We remain committed to advancing scientific progress, as demonstrated by our extensive record of research publications and clinical studies.

Gadovist® has demonstrated efficacy and a well established benefit-risk profile in more than 4000 studies, with several significant studies including DENSE, GadaCAD, LEADER-75, and GEMMA.

Reliable Supply

A Trusted Global Network

Bayer’s global supply network aims to provide you with a reliable supply of products by maintaining high safety and quality standards in adherence with good manufacturing practice (GMP) guidelines. We believe that reliable patient care depends on having a steady supply of high-quality contrast agents. That's why we have expanded our capacity to meet growing demands.. and offer 
Customized Business Models so you can take advantage of our solutions without added financial pressures or administrative complexity.

Image Quality
Enhancing More Than the Image

Backed by more than 4000 studies, Gadovist® enhances much more than just the quality of images. Learn how Gadovist® in combination with the Bayer portfolio helps you enhance more than the image.


    • 1
      Endrikat J, Gutberlet M, Barkhausen J, et al. Clinical Efficacy of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations. Invest Radiol. 2024;59(5):345-358. doi:10.1097/RLI.0000000000001041
    • 2
      Endrikat J, Gutberlet M, Hoffmann KT, et al. Clinical Safety of Gadobutrol: Review of Over 25 Years of Use Exceeding 100 Million Administrations. Invest Radiol. Published online March 1, 2024. doi:10.1097/RLI.0000000000001072
    • 3
      Bayer. About Us. Accessed 2024. https://www.radiology.bayer.com/about-us
    • 4
      European Society of Radiology (ESR). Impact of artificial intelligence on radiology: a EuroAIM survey among members of the European Society of Radiology. Insights Imaging. 2019;10(1):105.
    • 5
      Bayer. Annual Report 2021. Accessed 2024. https://www.bayer.com/sites/default/files/2022-03/Bayer-Annual-Report-2021.pdf
    • 6
      Bayer. Data on File.
    • 7
      Emaus MJ, et al. MR imaging as an additional screening modality for the detection of breast cancer in women aged 50–75 years with extremely dense breasts: the DENSE trial study design. Radiology. 2015;277(2):527-37.
    • 8
      Arai AE, et al. Gadobutrol-Enhanced Cardiac Magnetic Resonance Imaging for Detection of Coronary Artery Disease. J Am Coll Cardiol. 2020;76(13):1536-1547.
    • 9
      Liu BP, et al. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75). AJR Am J Roentgenol. 2021;217(5):1195-1205.
    • 10
      Sardanelli F, et al. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies. Invest Radiol. 2016;51(7):454-61.
    • 11
      Bayer. Kontrastmittel made in Germany. 2018. PP-GAD-DE-0028.
    • 12
      Bayer. Kontrastmittel made in Germany. Accessed 2024.https://www.radiologie.bayer.de/aktuelles/news/kontrastmittel-made-in-germany